经皮冠状动脉介入治疗后氯吡格雷与阿司匹林长期单药维持治疗的比较:HOST-EXAM试验10年随访
HOST-EXAM试验的10年延长随访纳入PCI术后完成6-18个月双联抗血小板治疗且无临床事件的患者,随机接受氯吡格雷75 mg每日一次或阿司匹林100 mg每日一次。中位随访10.5年,氯吡格雷组主要复合终点(全因死亡、非致死性心肌梗死、卒中、因急性冠脉综合征再入院及BARC≥3型出血)发生率低于阿司匹林组(25.4% vs 28.5%;HR 0.86,95%CI 0.77-0.96;log-rank P=0.0050)。氯吡格雷组血栓终点(17.3% vs 20.0%;P=0.0024)和出血终点(9.1% vs 10.8%;P=0.020)均较低,全因死亡率两组相似。作者认为这些结果支持在PCI术后慢性维持期考虑氯吡格雷作为阿司匹林长期抗血小板单药治疗的替代选择。
要点
- PCI术后完成6-18个月双联抗血小板治疗且无临床事件的患者,氯吡格雷75 mg每日一次较阿司匹林100 mg每日一次降低10年主要复合终点(25.4% vs 28.5%;HR 0.86,95%CI 0.77-0.96;P=0.0050)。
- 氯吡格雷组血栓终点发生率低于阿司匹林组(17.3% vs 20.0%;log-rank P=0.0024)。
- 氯吡格雷组出血终点发生率低于阿司匹林组(9.1% vs 10.8%;log-rank P=0.020)。
- 全因死亡率两组相似。
- 作者认为上述结果支持在PCI术后慢性维持期考虑氯吡格雷作为阿司匹林长期抗血小板单药治疗的替代选择。
适用人群与场景
- PCI术后完成双联抗血小板治疗6-18个月且无临床事件的患者。
处置流程与药物剂量
- 氯吡格雷75 mg每日一次口服。
- 阿司匹林100 mg每日一次口服。
研究设计与关键结果
- HOST-EXAM试验的10年延长随访,2014年3月26日至2018年5月29日入组5530例患者,5438例随机分配至阿司匹林组(n=2728)或氯吡格雷组(n=2710)。
- 临床随访状态于2025年5月1日确认,PCI后中位随访10.5年(IQR 9.4-11.4),完成率92.8%。
- 主要复合终点(全因死亡、非致死性心肌梗死、卒中、因急性冠脉综合征再入院及BARC≥3型出血):氯吡格雷组Kaplan-Meier估计25.4% vs 阿司匹林组28.5%(HR 0.86,95%CI 0.77-0.96;log-rank P=0.0050)。
- 血栓终点:氯吡格雷组17.3% vs 阿司匹林组20.0%(log-rank P=0.0024)。
- 出血终点:氯吡格雷组9.1% vs 阿司匹林组10.8%(log-rank P=0.020)。
- 全因死亡率两组相似。
证据类型、等级与局限
- 研究类型:HOST-EXAM试验的10年延长随访(研究者发起),主要分析为意向性治疗人群。
- 注册号:ClinicalTrials.gov NCT02044250。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些结果支持在PCI术后慢性维持期考虑氯吡格雷作为阿司匹林长期抗血小板单药治疗的替代选择。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The long-term clinical outcomes of clopidogrel monotherapy versus aspirin monotherapy after percutaneous coronary intervention (PCI) remain uncertain. We conducted a 10-year follow-up of the HOST-EXAM trial to assess the very long-term effects of clopidogrel versus aspirin monotherapy in this setting.
METHODS: In HOST-EXAM, patients who had completed dual antiplatelet therapy without clinical events for 6-18 months after PCI were randomly assigned to receive clopidogrel 75 mg once daily or aspirin 100 mg once daily. This study is an investigator-initiated 10-year extended follow-up of the HOST-EXAM trial. The primary endpoint was a composite of all-cause death, non-fatal myocardial infarction, stroke, readmission due to acute coronary syndrome, and Bleeding Academic Research Consortium type ≥3 bleeding. The primary analysis was done in the intention-to-treat population. The study is registered with ClinicalTrials.gov (NCT02044250) and is complete.
FINDINGS: From March 26, 2014, to May 29, 2018, 5530 patients were enrolled and 5438 were randomly assigned to the aspirin group (n=2728) or the clopidogrel group (n=2710). Clinical follow-up status was ascertained on May 1, 2025, resulting in a median follow-up duration of 10·5 years (IQR 9·4-11·4) after PCI and a completion rate of 92·8%. Clopidogrel was associated with a lower rate of the primary composite endpoint than aspirin (Kaplan-Meier estimate 25·4% for the clopidogrel group vs 28·5% for the aspirin group; hazard ratio 0·86 [95% CI 0·77-0·96]; log-rank p=0·0050). Clopidogrel was also associated with a lower rate of the thrombotic endpoint (17·3% vs 20·0%; log-rank p=0·0024) and bleeding endpoint (9·1% vs 10·8%; log-rank p=0·020). All-cause mortality was similar between groups.
INTERPRETATION: During 10 years of follow-up, clopidogrel monotherapy, compared with aspirin monotherapy, was associated with lower rates of the primary composite, ischaemic, and bleeding outcomes, but not all-cause mortality after PCI. These findings support consideration of clopidogrel as an alternative to aspirin for long-term antiplatelet monotherapy during the chronic maintenance phase after PCI.
FUNDING: Ministry of Health & Welfare, South Korea.
参考来源
- Kang J, Park S, Yang HM, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention: 10-year follow-up of the HOST-EXAM trial. Lancet. 2026. PMID: 41921522. doi:10.1016/S0140-6736(26)00422-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。